Latest Content

Experts Walk Through Recent Hematologic Malignancy Treatment Updates

June 19th 2025, 8:00pm

By Ryan Scott

Video

Dr. Raajit K. Rampal and Dr. Joshua K. Sabari walk through updates for patients in the treatment of blood cancers, including polycythemia vera.

Breaking Down the Impact of SERENA-6 for Some With Breast Cancer

June 19th 2025, 7:00pm

By Ryan Scott

Article

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

Why I Don’t Call Myself a Survivor With Metastatic Breast Cancer

June 19th 2025, 5:00pm

By Marissa Holzer

Article

Living with metastatic breast cancer, I find it hard to relate to the term “survivor.”

Why is Clinical Trial Enrollment Important for Those With Kidney Cancer?

June 19th 2025, 4:00pm

By Ryan Scott

Article

Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.

FDA Updates Talzenna-Xtandi Label for HRR-Mutated Metastatic Prostate Cancer

June 19th 2025, 3:00pm

By Spencer Feldman

Article

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.

Exploring Palliative and Curative Radiation for Lung Cancer

June 19th 2025, 1:00pm

By Dr. Jared Weiss

Article

Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms potentially boosting immune responses.

When a “Thinking of You” Card Isn’t the Right Support for a Patient

June 18th 2025, 9:00pm

By Sue McCarthy

Article

Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.

FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma

June 18th 2025, 8:00pm

By Spencer Feldman

Article

The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.

Recent SCLC Data May Impact How Patients Are Treated Day-to-Day

June 18th 2025, 7:12pm

By Ryan Scott

Article

Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.

I’m a Survivor: The Day I Finally Believed It

June 18th 2025, 5:00pm

By Tamron Little

Article

I finally felt like a survivor the day I heard my 18-month scans were clear, shifting from fear to faith and realizing I was not just surviving — I was thriving.

The Person Behind Their Diagnosis: Understanding the Patient

June 18th 2025, 4:26pm

By Ryan Scott

Article

Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

June 18th 2025, 3:00pm

By Spencer Feldman

Article

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

ctDNA-Guided Therapy May Improve Breast Cancer Outcomes

June 18th 2025, 1:00pm

By Dr. Julia E. McGuinness

Video

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

From Navigating the Unknown to Building a Movement: My DCIS Journey

June 17th 2025, 9:00pm

By Julia Stalder

Article

The bad news is you have ductal carcinoma in situ. The good news is that DCIS is the best type of breast cancer to get.

Zanzalintinib Triplet Combo Under Investigation in Kidney Cancer Subgroups

June 17th 2025, 8:00pm

By Dr. Michael Serzan

Video

Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma